Vaxcyte, Inc. — Director's Dealing 2024

Sep 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-09-17

Reporting Person: Loxam Teri (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-17	Common Stock	M	6250	$22.70	Acquired	13425	Direct
2024-09-17	Common Stock	S	241	$114.6372	Disposed	13184	Direct
2024-09-17	Common Stock	S	1445	$115.3176	Disposed	11739	Direct
2024-09-17	Common Stock	S	4308	$116.6172	Disposed	7431	Direct
2024-09-17	Common Stock	S	256	$117.51	Disposed	7175	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-17	Stock Option (right to buy)	$22.70	M	6250	Disposed	2032-05-31	Common Stock (6250)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.93 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $115.04 to $115.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $116.25 to $117.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F5: Option is fully vested and exercisable.